Lapatinib: An oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer

Sagar D. Sardesai, Anna Maria Storniolo

Research output: Contribution to journalReview article

4 Scopus citations


Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.

Original languageEnglish (US)
Pages (from-to)281-294
Number of pages14
JournalWomen's Health
Issue number3
StatePublished - Jun 1 2015


  • ERBB2
  • GW572016
  • HER-2
  • capecitabine
  • lapatinib
  • letrozole
  • metastatic breast cancer
  • trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Lapatinib: An oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer'. Together they form a unique fingerprint.

  • Cite this